Oxytocin does not directly alter cardiac repolarization in rabbit or human cardiac myocytes

Pharmacology Research and Perspectives

Volumn 3, Issue 1, 2015, Pages 1-11

  Qu, Yusheng ^a   Fang, Mei ^a   Gao, Baoxi ^a   Amagasu, Shanti ^a   Crumb, William J ^b   Vargas, Hugo M ^a  

^a AMGEN INC   (United States)

^b ZENAS TECHNOLOGIES LLC   (United States)

Author keywords

Action potential duration; APD90; Human ventricular myocytes; Ion channels; Isolated rabbit heart; Oxytocin; QT; QTc; Ventricular repolarization

Indexed keywords

CALCIUM ION; MOXIFLOXACIN; OXYTOCIN; POTASSIUM CHANNEL HERG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE POTENTIAL; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; QTC INTERVAL; RABBIT;

EID: 84934967292     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.102     Document Type: Article

References (41)

1. Abrams GM, Nilaver G, Recht LR, Haldar J, Zimmerman EA (1985). Hypothalamic oxytocin: a cerebrovascular modulator in man? Neurology 35: 1046-1049.
2. Amin AS, Herfst LJ, Delisle BP, Klemens CA, Rook MB, Bezzina CR, et al. (2008). Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. J Clin Invest 118: 2552-2561.
3. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ (2008). The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 84: 475-480.
4. Brooks DP, Share L, Crofton JT, Rockhold RW, Matsui K (1984). Effect of vertebral artery infusions of oxytocin on plasma vasopressin concentration, plasma renin activity, blood pressure and heart rate and their responses to hemorrhage. Neuroendocrinology 38: 382-386.
5. Charbit B, Funck-Brentano C, Samain E, Jannier-Guillou V, Albaladejo P, Marty J (2004). QT interval prolongation after oxytocin bolus during surgical induced abortion. Clin Pharmacol Ther 76: 359-364.
6. Charbit B, Funck-Brentano C, Benhamou D, Weissenburger J (2012). Effects of oxytocin on Purkinje fibres. Br J Anaesth 108: 1039-1041.
7. Cicutti NJ, Smyth CE, Rosaeg OP, Wilkinson M (1999). Oxytocin receptor binding in rat and human heart. Can J Cardiol 15: 1267-1273.
8. Coulson CC, Thorp JM Jr, Mayer DC, Cefalo RC (1997). Central hemodynamic effects of oxytocin and interaction with magnesium and pregnancy in the isolated perfused rat heart. Am J Obstet Gynecol 177: 91-93.
9. Desiderio MA, Hanson KM (1981). Splanchnic vascular effects of pharmacologic doses of oxytocin in the canine. Proc Soc Exp Biol Med 166: 432-437.
10. Evans JJ, Forrest OW, McArdle CA (1997). Oxytocin receptor-mediated activation of phosphoinositidase C and elevation of cytosolic calcium in the gonadotrope-derived alphaT3-1 cell line. Endocrinology 138: 2049-2055.
11. Fuchs AR, Goeschen K, Husslein P, Rasmussen AB, Fuchs F (1983). Oxytocin and initiation of human parturition. III. Plasma concentrations of oxytocin and 13, 14-dihydro-15-keto-prostaglandin F2 alpha in spontaneous and oxytocin-induced labor at term. Am J Obstet Gynecol 147: 497-502.
12. Gimpl G, Fahrenholz F (2001). The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81: 629-683.
13. Gintant GA (2011). An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129: 109-119.
14. Guillon A, Leyre S, Remerand F, Taihlan B, Perrotin F, Fusciardi J, et al. (2010). Modification of Tp-e and QTc intervals during caesarean section under spinal anaesthesia. Anaesthesia 65: 337-342.
15. Gutkowska J, Jankowski M (2012). Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol 24: 599-608.
16. Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM (1997). Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci USA 94: 11704-11709.
17. Hayashi S, Yoshihide K, Tabo M, Fukuda H, Itoh T, Shimosato T, et al. (2005). QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. J Pharmacol Sci 99: 423-437.
18. Heist EK, Ruskin JN (2010). Drug-induced arrhythmia. Circulation 122: 1426-1435.
19. Hsieh YC, Lin SF, Lin TC, Ting CT, Wu TJ (2009). Therapeutic hypothermia (30 degrees C) enhances arrhythmogenic substrates, including spatially discordant alternans, and facilitates pacing-induced ventricular fibrillation in isolated rabbit hearts. Circ J 73: 2214-2222.
20. Jasper JR, Harrell CM, O'Brien JA, Pettibone DJ (1995). Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci 57: 2253-2261.
21. Kolman BS, Verrier RL, Lown B (1976). Effect of vagus nerve stimulation upon excitability of the canine ventricle. Role of sympathetic-parasympathetic interactions. Am J Cardiol 37: 1041-1045.
22. Lawrence CL, Bridgland-Taylor MH, Pollard CE, Hammond TG, Valentin J-P (2006). A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsade de Pointes. Br J Pharmacol 149: 845-860.
23. Lee S, Harris ND, Robinson RT, Yeoh L, Macdonald IA, Heller SR (2003). Effects of adrenaline and potassium on QTc interval and QT dispersion in man. Eur J Clin Invest 33: 93-98.
24. Leitman DC, Agnost VL, Catalano RM, Schroder H, Waldman SA, Bennett BM, et al. (1988). Atrial natriuretic peptide, oxytocin, and vasopressin increase guanosine 3′, 5′-monophosphate in LLC-PK1 kidney epithelial cells. Endocrinology 122: 1478-1485.
25. Liou SC, Chen C, Wong SY, Wong KM (1998). Ventricular tachycardia after oxytocin injection in patients with prolonged Q-T interval syndrome-report of two cases. Acta Anaesthesiol Sin 36: 49-52.
26. Lown B, Verrier RL (1976). Neural activity and ventricular fibrillation. N Engl J. Med 294: 1165-1170.
27. Meenagh C, Mulholland C, Ryan MF (2004). Magnesium homeostasis and antipsychotic-induced QTc prolongation. J Psychopharmacol 18: 438-439.
28. Mitchell BF, Wong S (1995). Metabolism of oxytocin in human decidua, chorion, and placenta. J Clin Endocrinol Metab 80: 2729-2733.
29. Mukaddam-Daher S, Yin YL, Roy J, Gutkowska J, Cardinal R (2001). Negative inotropic and chronotropic effects of oxytocin. Hypertension 38: 292-296.
30. Nakano J, Fisher RD (1963). Studies on the cardiovascular effects of synthetic oxytocin. J Pharmacol Exp Ther 142: 206-214.
31. Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 12-21.
32. Qu Y, Fang M, Gao BX, Chui RW, Vargas HM (2011). BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart. J Pharmacol Exp Ther 337: 1-7.
33. Redfern WS, Caulsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
34. Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR (2003). Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes 52: 1469-1474.
35. Rosaeg OP, Cicutti NJ, Labow RS (1998). The effect of oxytocin on the contractile force of human atrial trabeculae. Anesth Analg 86: 40-44.
36. Spevak C, Hamsher C, Brown CQ, Wedam EF, Haigney MC (2012). The clinical significance of QT interval prolongation in anesthesia and pain management: what you should and should not worry about. Pain Med 13: 1072-1080.
37. Thomas TA, Cooper GM (2002). Maternal deaths from anaesthesia. An extract from Why Mothers Die 1997-1999, the Confidential Enquiries into Maternal Deaths in the United Kingdom. Br J Anaesth 89: 499-508.
38. Uzun M, Yapar K, Uzlu E, Citil M, Erdogan HM (2007). QT interval prolongation and decreased heart rates after intravenous bolus oxytocin injection in male and female conscious rabbits. Gen Physiol Biophys 26: 168-172.
39. Vargas HM, Bass AS, Breidenbach A, Feldman HS, Gintant GA, Harmer AR, et al. (2008). Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58: 72-76.
40. Vargas HM, Amouzadeh HR, Engwall MJ (2013). Non-clinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Expert Opin Drug Saf 12: 91-102.
41. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG (1954). The synthesis of oxytocin. J Am Chem Soc 76: 3115-3131.